[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"schizophreni-form-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:schizophreni-form-disorder":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,55],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":4},"100655961","building-a-computational-model-of-auditory-hallucinations-100655961",false,"NCT07820553","Building a Computational Model of Auditory Hallucinations","Building a Computational Model of the Role of Excitation\u002FInhibition (E\u002FI) Balance in Auditory Hallucinations Using Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI): a Case-control Study","CLARITY WP1","Inclusion Criteria:\n\nPWLEP:\n\n1. Age 16-65 years.\n2. A score of at least 3 on the state section of the Auditory Perceptual Trait and State scale (APTS).\n3. If using an antipsychotic drug, participants must be on a stable dose of any medication during the baseline measures.\n4. Sufficient understanding of the nature of the study and any hazards of participating in it, or suitable consultee who can understand this and provide an opinion of what the participant's wishes would be if the participant does not have capacity, if appropriate to do so.\n5. Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire study.\n6. Capacity to give written consent to participate after reading the information and consent form and after having the opportunity to discuss the study with the investigators or their delegates, or suitable consultee who can understand this and provide an opinion of what the participant's wishes would be if the participant does not have capacity, if appropriate to do so.\n\nHealthy controls:\n\n1. Age 16-65 years.\n2. Sufficient understanding of the nature of the study and any hazards of participating in it, or suitable consultee who can understand this and provide an opinion of what the participant's wishes would be if the participant does not have capacity, if appropriate to do so.\n3. Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire study.\n4. Capacity to give written consent to participate after reading the information and consent form and after having the opportunity to discuss the study with the investigators or their delegates, or suitable consultee who can understand this and provide an opinion of what the participant's wishes would be if the participant does not have capacity, if appropriate to do so.\n\nExclusion Criteria:\n\nPWLEP:\n\n1. Clinically relevant abnormal history, or laboratory values at the pre-study screening assessment or participation in other research studies that could interfere with the objectives of the study or the safety of the participant, as deemed significant for a study researcher.\n2. Impaired endocrine, cardiac, pulmonary, thyroid, haematological, hepatic, respiratory, neurological, immunological or renal function, or other major disease (e.g. cancer) deemed clinically significant at the time of the study.\n3. Recent history (i.e. in the last 12 months) of epilepsy or seizures.\n4. Homicidal ideation or intent, as judged by a researcher; suicidal ideation, with some intent to act, or suicidal behaviour, as judged by a researcher.\n5. History of drug or alcohol dependence (except for caffeine and nicotine and mild\u002Fmoderate cannabis dependence) in the 3 months before study start.\n6. Likelihood that the participant will not comply with the requirements of the protocol.\n7. Contraindication to MRI, EEG or other study procedures (for example history of metal implants or metal pieces entering the body that cannot be removed safely, severe claustrophobia, allergy or skin sensitivity to EEG electrode gel).\n8. Any other condition or disability that would make participation in the study procedures not possible (for example severe vision or hearing impairment).\n\nHealthy controls:\n\nAs above, and also:\n\n1\\. No relevant family history of schizophrenia and psychosis (as judged relevant by a study researcher).",true,"ALL","16 Years","65 Years",{"count":22,"type":23},146,"ESTIMATED","OBSERVATIONAL","Some people hear voices or sounds that other people cannot hear; these are called auditory hallucinations. The study aims to understand what is happening in the brain when this occurs and will use brain scans to learn more. Greater understanding should help develop better treatments in the future.",[27,28,29,30,31],"Schizophrenia \u002F Schizoaffective Disorder","Schizophrenia and Disorders With Psychotic Feature","Psychosis","SCHIZOPHRENIA 1 (Disorder)","Schizophreni-form Disorder",[33,34,35,36,37,38,39,40,41,42],"schizophrenia","EEG","E\u002FI balance","electrophysiology","computational models","auditory hallucinations","MRI","psychosis","computational psychiatry","neuroimaging","NOT_YET_RECRUITING","2026-09-14",{"date":46,"type":47},"2026-09-15","ACTUAL",{"date":49,"type":23},"2026-09",{"date":51,"type":23},"2030-08",{"name":53,"class":54},"King's College London","OTHER",{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":18,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":79,"leadSponsor":81,"locationsCount":4},"100655408","mobile-application-based-interventions-for-cannabis-use-in-young-adults-with-first-episode-psychosis-100655408","NCT07811466","Mobile Application-Based Interventions for Cannabis Use in Young Adults With First Episode Psychosis","Mobile Health","Inclusion Criteria:\n\nCHAMPS INTERVENTION\n\n* Young adults (18-35 years) with FEP\n* Cannabis use ≥1 day in the past month\n* MPS score ≥2,\n* NOT seeking treatment for cannabis use disorder (CUD).\n* CUD diagnosis possible but not required.\n* With a minimum of 2 months of follow-up at an EIS clinic.\n\nI CAN CHANGE INTERVENTION\n\n* Young adults (18-35 years) with FEP and CUD (DSM-5, moderate to severe)\n* Seeking to reduce or cease use\n* With a minimum of 2 months of follow-up at an EIS clinic.\n\nExclusion Criteria:\n\n* Pregnancy, breastfeeding, or any medical condition that, in the opinion of the psychiatrist, precludes safe participation or the ability to provide informed consent,\n* Any disabling, unstable, or acute mental condition that, in the opinion of the psychiatrist, precludes safe participation or the ability to provide informed consent,\n* Any planned extended absence (pending legal action, surgery, inpatient program) or other reason that, in the opinion of the study team, might prevent completion of the study,\n* Presence of a substance use disorder that, in the opinion of the psychiatrist, precludes safe participation (e.g., very unstable or severe SUD),\n* Currently participating in another specific cannabis use-focused intervention.","18 Years","35 Years",{"count":65,"type":23},550,"INTERVENTIONAL",[68],"NA","Psychotic disorders affect approximately 4% of Canadians and have a significant impact on individuals' well-being, their families and social networks, and healthcare systems. The development of psychosis is explained by a complex interplay of genetic and environmental factors, including the use of psychoactive substances. Frequent cannabis use can contribute to the development of psychotic disorders.\n\nThe prevalence of cannabis use disorder (CUD) in individuals with a first-episode psychosis (FEP) followed in Early Intervention Services (EIS) is 42-53%, well above that of the general population (\\~3%). Cannabis use in individuals with psychosis is associated with increased symptom severity, higher rates of relapse and hospitalization, and poor psychosocial functioning.\n\nStandardized mobile app-based interventions offer a scalable and accessible solution. Our team developed and piloted CHAMPS (harm reduction) and iCanChange (use reduction\u002Fcessation) with favourable results: retention 82% (CHAMPS) and 84-86% (iCC), high satisfaction, and preliminary efficacy signals. The two pilot studies were targeting feasibility, this study is studying efficacy of the two app-based interventions (CHAMPS and iCanChange).",[71,29,31,72],"First Episode Psychosis (FEP)","Dependence Addictive",[74],"Adults 18-35 years old who had a first episode psychosis and are using cannabis","2026-09-03",{"date":77,"type":47},"2026-09-10",{"date":46,"type":23},{"date":80,"type":23},"2031-04-15",{"name":82,"class":54},"Centre hospitalier de l'Université de Montréal (CHUM)"]